Utility of models of the gastrointestinal tract for assessment of the digestion and absorption of engineered nanomaterials released from food matrices

Nanotoxicology

Volumn 9, Issue 4, 2015, Pages 523-542

  Lefebvre, David E ^a   Venema, Koen ^b   Gombau, Lourdes ^c   Valerio, Luis G ^d   Raju, Jayadev ^a   Bondy, Genevieve S ^a   Bouwmeester, Hans ^e   Singh, R Paul ^f   Clippinger, Amy J ^g   Collnot, Eva Maria ^h   Mehta, Rekha ^a   Stone, Vicki ⁱ  

^a TOXICOLOGY RESEARCH DIVISION   (Canada)

^b Beneficial Microbes Consultancy   (Netherlands)

^c LEITAT TECHNOLOGICAL CENTER   (Spain)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e WAGENINGEN UNIVERSITY   (Netherlands)

^f Univ of California   (United States)

^g PETA International Science Consortium Ltd   (United Kingdom)

^h URSAPHARM Industries   (Germany)

ⁱ HERIOT WATT UNIVERSITY   (United Kingdom)

Author keywords

Alimentary canal; Bioaccessibility; Bioavailability; Nanotechnology

Indexed keywords

GOLD NANOPARTICLE; NANOMATERIAL; SILVER NANOPARTICLE; TITANIUM DIOXIDE NANOPARTICLE;

ABERRANT CRYPT FOCUS; ARTIFICIAL MEMBRANE; CELL MEMBRANE; COMPUTER MODEL; DIGESTION; EPITHELIUM CELL; EX VIVO STUDY; FOOD; GASTROINTESTINAL TRACT; GASTROINTESTINAL TUMOR; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INTESTINE ABSORPTION; INTESTINE POLYP; LAMINA PROPRIA; LARGE INTESTINE; MOUTH CAVITY; MUCOADHESION; MUCUS; NONHUMAN; PERMEABILITY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMALL INTESTINE; STOMACH; ANIMAL; BIOLOGICAL MODEL; PHYSIOLOGY;

ANIMALIA;

ANIMALS; DIGESTION; FOOD; GASTROINTESTINAL TRACT; HUMANS; MODELS, BIOLOGICAL; NANOSTRUCTURES;

EID: 84929721955     PISSN: 17435390     EISSN: 17435404     Source Type: Journal    
DOI: 10.3109/17435390.2014.948091     Document Type: Review

References (184)

1. Ahmed SS, Ramakrishnan V. 2012. Systems biological approach of molecular descriptors connectivity: optimal descriptors for oral bioavailability prediction. PLoS One 7:e40654.
2. Alam MA, Al-Jenoobi FI, Al-Mohizea AM. 2012. Everted gut sac model as a tool in pharmaceutical research: limitations and applications. J Pharm Pharmacol 64:326-36.
3. Alger H, Momcilovic D, Carlander D, Duncan TV. 2014. Methods to evaluate uptake of engineered nanomaterials by the alimentary tract. Compr Rev Food Sci Food Saf 13:705-29.
4. Avdeef A, Tam KY. 2010. How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? J Med Chem 53:3566-84.
5. Bachler G, von Goetz N, Hungerbuhler K. 2013. A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles. Int J Nanomedicine 8:3365-82.
6. Behrens I, Pena AI, Alonso MJ, Kissel T. 2002. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm Res 19:1185-93.
7. Bihari P, Vippola M, Schultes S, Praetner M, Khandoga AG, Reichel CA, et al. 2008. Optimized dispersion of nanoparticles for biological in vitro and in vivo studies. Part Fibre Toxicol 5:14. doi:10.1186/1743- 8977-5-14.
8. Blanquet S, Zeijdner E, Beyssac E, Meunier JP, Denis S, Havenaar R, Alric M. 2004. A dynamic artificial gastrointestinal system for studying the behavior of orally administered drug dosage forms under various physiological conditions. Pharm Res 21:585-91.
9. Bohmert L, Girod M, Hansen U, Maul R, Knappe P, Niemann B, et al. 2013. Analytically monitored digestion of silver nanoparticles and their toxicity for human intestinal cells. Nanotoxicology 8:631-42.
10. Bolger MB, Lukacova V, Woltosz WS. 2009. Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine. AAPS J 11:353-63.
11. Bouwmeester H, Dekkers S, Noordam MY, Hagens WI, Bulder AS, de Heer C, et al. 2009. Review of health safety aspects of nanotechnologies in food production. Regul Toxicol Pharmacol 53:52-62.
12. Bouwmeester H, Lynch I, Marvin HJ, Dawson KA, Berges M, Braguer D, et al. 2011a. Minimal analytical characterization of engineered nanomaterials needed for hazard assessment in biological matrices. Nanotoxicology 5:1-11.
13. Bouwmeester H, Poortman J, Peters RJ, Wijma E, Kramer E, Makama S, et al. 2011b. Characterization of translocation of silver nanoparticles and effects on whole-genome gene expression using an in vitro intestinal epithelium coculture model. ACS Nano 5:4091-103.
14. Brandon EF, Oomen AG, Rompelberg CJ, Versantvoort CH, van Engelen JG, Sips AJ. 2006. Consumer product in vitro digestion model: bioaccessibility of contaminants and its application in risk assessment. Regul Toxicol Pharmacol 44:161-71.
15. Buckley ST, Fischer SM, Fricker G, Brandl M. 2012. In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives. Eur J Pharm Sci 45:235-50.
16. Camilleri M, Madsen K, Spiller R, Greenwood-Van Meerveld B, Verne GN. 2012. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 24:503-12.
17. Canady RA. 2010. The uncertainty of nanotoxicology: report of a society for risk analysis workshop. Risk Anal 30:1663-70.
18. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, et al. 2006. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675-86.
19. Card JW, Jonaitis TS, Tafazoli S, Magnuson BA. 2011. An appraisal of the published literature on the safety and toxicity of food-related nanomaterials. Crit Rev Toxicol 41:22-49.
20. Carreno-Gomez B, Woodley JF, Florence AT. 1999. Studies on the uptake of tomato lectin nanoparticles in everted gut sacs. Int J Pharm 183: 7-11.
21. Chen XM, Elisia I, Kitts DD. 2010. Defining conditions for the co-culture of Caco-2 and HT29-MTX cells using Taguchi design. J Pharmacol Toxicol Methods 61:334-42.
22. Chen YK, Lin LM. 2010. DMBA-induced hamster buccal pouch carcinoma and VX2-induced rabbit cancer as a model for human oral carcinogenesis. Exp Rev Anticancer Ther 10:1485-96.
23. Choi SS, Kim JS, Valerio Jr LG, Sadrieh N. 2013. In silico modeling to predict drug-induced phospholipidosis. Toxicol Appl Pharmacol 269: 195-204.
24. Chopra DP, Dombkowski AA, Stemmer PM, Parker GC. 2010. Intestinal epithelial cells in vitro. Stem cells Dev 19:131-42.
25. Christensen J, El-Gebali S, Natoli M, Sengstag T, Delorenzi M, Bentz S, et al. 2012. Defining new criteria for selection of cell-based intestinal models using publicly available databases. BMC Genomics 13:274.
26. Cinquin C, Le Blay G, Fliss I, Lacroix C. 2004. Immobilization of infant fecal microbiota and utilization in an in vitro colonic fermentation model. Microb Ecol 48:128-38.
27. Cockburn A, Bradford R, Buck N, Constable A, Edwards G, Haber B, et al. 2012. Approaches to the safety assessment of engineered nanomaterials (ENM) in food. Food Chem Toxicol 50:2224-42.
28. Coco R, Plapied L, Pourcelle V, Jerome C, Brayden DJ, Schneider YJ, Preat V. 2013. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int J Pharm 440:3-12.
29. Cohen J, Deloid G, Pyrgiotakis G, Demokritou P. 2013. Interactions of engineered nanomaterials in physiological media and implications for in vitro dosimetry. Nanotoxicology 7:417-31.
30. Costea DE, Johannessen AC, Vintermyr OK. 2005. Fibroblast control on epithelial differentiation is gradually lost during in vitro tumor progression. Differentiation 73:134-41.
31. Crater JS, Carrier RL. 2010. Barrier properties of gastrointestinal mucus to nanoparticle transport. Macromol Biosci 10:1473-83.
32. Deat E, Blanquet-Diot S, Jarrige JF, Denis S, Beyssac E, Alric M. 2009. Combining the dynamic TNO-gastrointestinal tract system with a Caco-2 cell culture model: application to the assessment of lycopene and alpha-tocopherol bioavailability from a whole food. J Agric Food Chem 57:11314-20.
33. Dekkers S, Krystek P, Peters RJ, Lankveld DP, Bokkers BG, van Hoeven- Arentzen PH, et al. 2011. Presence and risks of nanosilica in food products. Nanotoxicology 5:393-405.
34. DeLoid G, Cohen JM, Darrah T, Derk R, Rojanasakl L, Pyrgiotakis G, et al. 2014. Estimating the effective density fo engineered nanomaterials for in vitro dosimetry. Nat Commun 5:3514. doi:10.1038/ncomms4514.
35. des Rieux A, Fievez V, Theate I, Mast J, Preat V, Schneider YJ. 2007. An improved in vitro model of human intestinal follicle-Associated epithelium to study nanoparticle transport by m cells. Eur J Pharm Sci 30:380-91.
36. Donato RP, El-Merhibi A, Gundsambuu B, Mak KY, Formosa ER, Wang X, et al. 2011. Studying permeability in a commonly used epithelial cell line: T84 intestinal epithelial cells. Methods Mol Biol 763:115-37.
37. Dunnhaupt S, Barthelmes J, Hombach J, Sakloetsakun D, Arkhipova V, Bernkop-Schnurch A. 2011. Distribution of thiolated mucoadhesive nanoparticles on intestinal mucosa. Int J Pharm 408:191-9.
38. Fisichella M, Berenguer F, Steinmetz G, Auffan M, Rose J, Prat O. 2012a. Intestinal toxicity evaluation of TiO2 degraded surface-treated nanoparticles: a combined physico-chemical and toxicogenomics approach in Caco-2 cells. Part Fibre Toxicol 9:18.
39. Fisichella M, Berenguer F, Steinmetz G, Auffan M, Rose J, Prat O. 2012b. Reply to comment on Fisichella et al. (2012), Intestinal toxicity evaluation of TiO2 degraded surface-treated nanoparticles: a combined physico-chemical and toxicogenomics approach in Caco-2 cells by Faust et al. Part Fibre Toxicol 9:39. doi:10.1186/1743-8977-9-39.
40. Frohlich E. 2012. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine 7:5577-91.
41. Frontela-Saseta C, Lopez-Nicolas R, Gonzalez-Bermudez CA, Martinez- Gracia C, Ros-Berruezo G. 2013. Anti-inflammatory properties of fruit juices enriched with pine bark extract in an in vitro model of inflamed human intestinal epithelium: the effect of gastrointestinal digestion. Food Chem Toxicol 53:94-9.
42. Gaiser BK, Fernandes TF, Jepson MA, Lead JR, Tyler CR, Baalousha M, et al. 2012. Interspecies comparisons on the uptake and toxicity of silver and cerium dioxide nanoparticles. Environ Toxicol Chem 31: 144-54.
43. Gamboa JM, Leong KW. 2013. In vitro and in vivo models for the study of oral delivery of nanoparticles. Adv Drug Deliv Rev 65:800-10.
44. Garman KS, Orlando RC, Chen X. 2012. Review: experimental models for Barretts esophagus and esophageal adenocarcinoma. Am J Physiol Gastrointest Liver Physiol 302:G1231-43.
45. Garrett NL, Lalatsa A, Uchegbu I, Schatzlein A, Moger J. 2012. Exploring uptake mechanisms of oral nanomedicines using multimodal nonlinear optical microscopy. J Biophoton 5:458-68.
46. Ghoddusi HB, Grandison MA, Grandison AS, Tuohy KM. 2007. In vitro study on gas generation and prebiotic effects of some carbohydrates and their mixtures. Anaerobe 13:193-9.
47. Gibson N, Holzwarth U, Abbas K, Simonelli F, Kozempel J, Cydzik I, et al. 2011. Radiolabelling of engineered nanoparticles for in vitro and in vivo tracing applications using cyclotron accelerators. Arch Toxicol 85:751-73.
48. Giovino C, Ayensu I, Tetteh J, Boateng JS. 2013. An integrated buccal delivery system combining chitosan films impregnated with peptide loaded PEG-b-PLA nanoparticles. Colloids Surf B Biointerfaces 112: 9-15.
49. Gracz AD, Fuller MK, Wang F, Li L, Stelzner M, Dunn JC, et al. 2013. Brief report: CD24 and CD44 mark human intestinal epithelial cell populations with characteristics of active and facultative stem cells. Stem cells 31:2024-30.
50. Guhmann M, Thommes M, Gerber F, Pollinger N, Klein S, Breitkreutz J, WeitschiesW. 2013. Design of biorelevant test setups for the prediction of diclofenac in vivo features after oral administration. Pharm Res 30: 1483-501.
51. Gupta AK, Pretlow TP, Schoen RE. 2007. Aberrant crypt foci: ehat we know and what we need to know. Clin Gastroenterol Hepatol 5:526-33.
52. Hagens WI, Oomen AG, de Jong WH, Cassee FR, Sips AJ. 2007. What do we (need to) know about the kinetic properties of nanoparticles in the body? Regul Toxicol Pharmacol 49:217-29.
53. Hassani S, Pellequer Y, Lamprecht A. 2009. Selective adhesion of nanoparticles to inflamed tissue in gastric ulcers. Pharm Res 26: 1149-54.
54. Hinderliter PM, Minard KR, Orr G, Chrisler WB, Thrall BD, Pounds JG, Teeguarden JG. 2010. ISDD: a computational model of particle sedimentation, diffusion and target cell dosimetry for in vitro toxicity studies. Part Fibre Toxicol 7:36. doi:10.1186/1743-8977-7-36.
55. Huizer D, Oldenkamp R, Ragas AM, van Rooij JG, Huijbregts MA. 2012. Separating uncertainty and physiological variability in human pbpk modelling: the example of 2-propanol and its metabolite acetone. Toxicol Lett 214:154-65.
56. Izumo T. 2011. Oral premalignant lesions: from the pathological viewpoint. Int J Clin Oncol 16:15-26.
57. Jahn MR, Shukoor I, Tremel W, Wolfrum U, Kolb U, Nawroth T, Langguth P. 2011. Hemin-coupled iron (iii)-hydroxide nanoparticles show increased uptake in Caco-2 cells. J Pharm Pharmacol 63: 1522-30.
58. Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, Tucker G. 2009. Population-based mechanistic prediction of oral drug absorption. AAPS J 11:225-37.
59. Jani PU, McCarthy DE, Florence AT. 1994. Titanium dioxide (rutile) particle uptake from the rat GI tract and translocation to systemic organs after oral administration. Int J Pharm 105:157-68.
60. Johnston H, Pojana G, Zuin S, Jacobsen NR, Moller P, Loft S, et al. 2013. Engineered nanomaterial risk. Lessons learnt from completed nanotoxicology studies: potential solutions to current and future challenges. Crit Rev Toxicol 43:1-20.
61. Jubeh TT, Barenholz Y, Rubinstein A. 2004. Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharm Res 21:447-53.
62. Kadiyala I, Loo Y, Roy K, Rice J, Leong KW. 2010. Transport of chitosan-DNA nanoparticles in human intestinal M-cell model versus normal intestinal enterocytes. Eur J Pharm Sci 39:103-9.
63. Kenzaoui BH, Vila MR, Miquel JM, Cengelli F, Juillerat-Jeanneret L. 2012. Evaluation of uptake and transport of cationic and anionic ultrasmall iron oxide nanoparticles by human colon cells. Int J Nanomedicine 7:1275-86.
64. Kim HJ, Huh D, Hamilton G, Ingber DE. 2012. Human gut-on-A-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab on a chip 12:2165-74.
65. Kim HJ, Ingber DE. 2013. Gut-on-A-chip microenvironment induces human intestinal cells to undergo villus differentiation. Integr Biol (Camb) 5:1130-40.
66. Kim JS, Mitchell S, Kijek P, Tsume Y, Hilfinger J, Amidon GL. 2006. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Mol Pharm 3:686-94.
67. Koeneman BA, Zhang Y, Westerhoff P, Chen Y, Crittenden JC, Capco DG. 2010. Toxicity and cellular responses of intestinal cells exposed to titanium dioxide. Cell Biol Toxicol 26:225-38.
68. Kong F, Oztop MH, Singh RP, McCarthy MJ. 2011. Physical changes in white and brown rice during simulated gastric digestion. J Food Sci 76: E450-7.
69. Kong F, Singh RP. 2008. A model stomach system to investigate disintegration kinetics of solid foods during gastric digestion. J Food Sci 73:E202-10.
70. Kong F, Singh RP. 2010. A human gastric simulator (HGS) to study food digestion in human stomach. J Food Sci 75:E627-35.
71. Kopf-Bolanz KA, Schwander F, Gijs M, Vergeres G, Portmann R, Egger L. 2012. Validation of an in vitro digestive system for studying macronutrient decomposition in humans. J Nutr 142:245-50.
72. Lai CH, Chang NW, Lin CF, Lin CD, Lin YJ, Wan L, et al. 2010. Proteomics-based identification of haptoglobin as a novel plasma biomarker in oral squamous cell carcinoma. Clin Chim Acta 411: 984-91.
73. Lambros MP, Parsa C, Mulamalla H, Orlando R, Lau B, Huang Y, et al. 2011. Identifying cell and molecular stress after radiation in a threedimensional (3-D) model of oral mucositis. Biochem Biophys Res Commun 405:102-6.
74. Lamprecht A, Schafer U, Lehr CM. 2001. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res 18:788-93.
75. Larner F, Dogra Y, Dybowska A, Fabrega J, Stolpe B, Bridgestock LJ, et al. 2012. Tracing bioavailability of ZnO nanoparticles using stable isotope labeling. Environ Sci Technol 46:12137-45.
76. Lee CM, Jeong HJ, Yun KN, Kim DW, Sohn MH, Lee JK, et al. 2012. Optical imaging to trace near infrared fluorescent zinc oxide nanoparticles following oral exposure. Int J Nanomedicine 7:3203-9.
77. Lefebvre DE, Pearce B, Fine J, Chomyshyn E, Ross N, Halappanavar S, et al. 2014. In vitro enhancement of mouse T helper 2 cell sensitization to ovalbumin allergen by carbon black nanoparticles. Toxicol Sci 138: 322-32.
78. Lefebvre DE, Powell KL, Strom A, Scott FW. 2006. Dietary proteins as environmental modifiers of type 1 diabetes mellitus. Annu Rev Nutr 26:175-202.
79. Lennernas H. 2007. Animal data: the contributions of the ussing chamber and perfusion systems to predicting human oral drug delivery in vivo. Adv Drug Deliv Rev 59:1103-20.
80. Lennernas H, Lee ID, Fagerholm U, Amidon GL. 1997. A residence-time distribution analysis of the hydrodynamics within the intestine in man during a regional single-pass perfusion with Loc-I-Gut: in-vivo permeability estimation. J Pharm Pharmacol 49:682-6.
81. Leonard F, Ali H, Collnot EM, Crielaard BJ, Lammers T, Storm G, Lehr CM. 2012. Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3d cell-culture model. ALTEX 29:275-85.
82. Leonard F, Collnot EM, Lehr CM. 2010. A three-dimensional coculture of enterocytes, monocytes and dendritic cells to model inflamed intestinal mucosa in vitro. Mol Pharm 7:2103-19.
83. Liebsch M, Grune B, Seiler A, Butzke D, Oelgeschlager M, Pirow R, et al. 2011. Alternatives to animal testing: current status and future perspectives. Arch Toxicol 85:841-58.
84. Linnankoski J, Ranta VP, Yliperttula M, Urtti A. 2008. Passive oral drug absorption can be predicted more reliably by experimental than computational models - fact or myth. Eur J Pharm Sci 34:129-39.
85. Llabot JM, Salman H, Millotti G, Bernkop-Schnurch A, Allemandi D, Manuel Irache J. 2011. Bioadhesive properties of poly(anhydride) nanoparticles coated with different molecular weights chitosan. J Microencapsul 28:455-63.
86. Loeschner K, Hadrup N, Qvortrup K, Larsen A, Gao X, Vogel U, et al. 2011. Distribution of silver in rats following 28 days of repeated oral exposure to silver nanoparticles or silver acetate. Part Fibre Toxicol 8:18. doi:10.1186/1743-8977-8-18.
87. Luo T, Huang P, Gao G, Shen G, Fu S, Cui D, et al. 2011. Mesoporous silica-coated gold nanorods with embedded indocyanine green for dual mode X-ray CT and NIR fluorescence imaging. Opt Express 19: 17030-9.
88. Macfarlane GT, Macfarlane S, Gibson GR. 1998. Validation of a threestage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microb Ecol 35:180-7.
89. Makivuokko H, Nurmi J, Nurminen P, Stowell J, Rautonen N. 2005. In vitro effects on polydextrose by colonic bacteria and Caco-2 cell cyclooxygenase gene expression. Nutr Cancer 52:94-104.
90. McAllister M. 2010. Dynamic dissolution: a step closer to predictive dissolution testing? Mol Pharm 7:1374-87.
91. McCracken C, Zane A, Knight DA, Dutta PK, Waldman WJ. 2013. Minimal intestinal epithelial cell toxicity in response to short- and long-term food-relevant inorganic nanoparticle exposure. Chem Res Toxicol 26:1514-25.
92. Mercuri A, Passalacqua A, Wickham MS, Faulks RM, Craig DQ, Barker SA. 2011. The effect of composition and gastric conditions on the selfemulsification process of ibuprofen-loaded self-emulsifying drug delivery systems: a microscopic and dynamic gastric model study. Pharm Res 28:1540-51.
93. Meresse B, Malamut G, Cerf-Bensussan N. 2012. Celiac disease: an immunological jigsaw. Immunity 36:907-19.
94. Minekus M, Smeets-Peeters M, Bernalier A, Marol-Bonnin S, Havenaar R, Marteau P, et al. 1999. A computer-controlled system to simulate conditions of the large intestine with peristaltic mixing, water absorption and absorption of fermentation products. Appl Microbiol Biotechnol 53:108-14.
95. Miret S, Abrahamse L, de Groene EM. 2004. Comparison of in vitro models for the prediction of compound absorption across the human intestinal mucosa. J Biomol Screen 9:598-606.
96. Misra SK, Dybowska A, Berhanu D, Luoma SN, Valsami-Jones E. 2012. The complexity of nanoparticle dissolution and its importance in nanotoxicological studies. Sci Total Environ 438:225-32.
97. Mizoguchi A. 2012. Animal models of inflammatory bowel disease. Prog Mol Biol Transl Sci 105:263-320.
98. Moda TL, Andricopulo AD. 2012. Consensus hologram QSAR modeling for the prediction of human intestinal absorption. Bioorg Med Chem Lett 22:2889-93.
99. Moharamzadeh K, Brook IM, Van Noort R, Scutt AM, Smith KG, Thornhill MH. 2008. Development, optimization and characterization of a full-thickness tissue engineered human oral mucosal model for biological assessment of dental biomaterials. J Mater Sci Mater Med 19:1793-801.
100. Molly K, Vande Woestyne M, Verstraete W. 1993. Development of a 5- step multi-chamber reactor as a simulation of the human intestinal microbial ecosystem. Appl Microbiol Biotechnol 39:254-8.
101. Mwilu SK, El Badawy AM, Bradham K, Nelson C, Thomas D, Scheckel KG, et al. 2013. Changes in silver nanoparticles exposed to human synthetic stomach fluid: effects of particle size and surface chemistry. Sci Total Environ 447:90-8.
102. Natoli M, Leoni BD, DAgnano I, Zucco F, Felsani A. 2012. Good Caco-2 cell culture practices. Toxicol In Vitro 26:1243-6.
103. Nel AE, Nasser E, Godwin H, Avery D, Bahadori T, Bergeson L, et al. 2013. A multi-stakeholder perspective on the use of alternative test strategies for nanomaterial safety assessment. ACS Nano 7: 6422-33.
104. Neun BW, Dobrovolskaia MA. 2011. Detection and quantitative evaluation of endotoxin contamination in nanoparticle formulations by LALbased assays. Methods Mol Biol 697:121-30.
105. Neurath MF. 2012. Animal models of inflammatory bowel diseases: illuminating the pathogenesis of colitis, ileitis and cancer. Dig Dis 30 1:91-4.
106. Noonan GO, Whelton AJ, Carlander D, Duncan TV. 2014. Measurement methods to evaluate engineered nanomaterial release from food contact materials. Compr Rev Food Sci Food Safety 13:679-92.
107. Nwokolo CU, Lewin JF, Hudson M, Pounder RE. 1992. Transmucosal penetration of bismuth particles in the human stomach. Gastroenterology 102:163-7.
108. OECD, 2000. Guidance document on recognition, assessment and use of clinical signs as humane endpoints for experimental animals used in safety evaluation. OECD environmental health and safety publications ENV/JM/MONO, No 19.
109. OECD. 2010. Toxicokinetics. OECD Guideline for the testing of chemicals Section 4:417.
110. OECD. 2012. Guidance on sample preparation and dosimetry for the safety testing of manufactured nanomaterials. OECD Environmental Health and Safety Publications ENV/JM/MONO:No 40.
111. Paek HJ, Lee YJ, Chung HE, Yoo NH, Lee JA, Kim MK, et al. 2013. Modulation of the pharmacokinetics of zinc oxide nanoparticles and their fates in vivo. Nanoscale 5:11416-27.
112. Paixao P, Gouveia LF, Morais JA. 2012. Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model. Int J Pharm 429:84-98.
113. Park K, Park EJ, Chun IK, Choi K, Lee SH, Yoon J, Lee BC. 2011. Bioavailability and toxicokinetics of citrate-coated silver nanoparticles in rats. Arch Pharm Res 34:153-8.
114. Patel N, Forbes B, Eskola S, Murray J. 2006. Use of simulated intestinal fluids with Caco-2 cells and rat ileum. Drug Dev Ind Pharm 32: 151-61.
115. Pelkonen O, Boobis AR, Gundert-Remy U. 2001. In vitro prediction of gastrointestinal absorption and bioavailability: an experts meeting report. Eur J Clin Pharmacol 57:621-9.
116. Peters R, Kramer E, Oomen AG, Rivera ZE, Oegema G, Tromp PC, et al. 2012. Presence of nano-sized silica during in vitro digestion of foods containing silica as a food additive. ACS Nano 6:2441-51.
117. Powell JJ, Ainley CC, Harvey RS, Mason IM, Kendall MD, Sankey EA, et al. 1996. Characterisation of inorganic microparticles in pigment cells of human gut associated lymphoid tissue. Gut 38:390-5.
118. Powell JJ, Faria N, Thomas-McKay E, Pele LC. 2010. Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 34:J226-33.
119. Prieto P, Hoffmann S, Tirelli V, Tancredi F, Gonzalez I, Bermejo M, De Angelis I. 2010. An exploratory study of two Caco-2 cell models for oral absorption: a report on their within-laboratory and betweenlaboratory variability, and their predictive capacity. Altern Lab Anim 38:367-86.
120. Pusch J, Votteler M, Gohler S, Engl J, Hampel M, Walles H, Schenke- Layland K. 2011. The physiological performance of a three-dimensional model that mimics the microenvironment of the small intestine. Biomaterials 32:7469-78.
121. Raju J. 2008. Azoxymethane-induced rat aberrant crypt foci: relevance in studying chemoprevention of colon cancer. World J Gastroenterol 14: 6632-5.
122. Raju J, Bird RP. 2003. Energy restriction reduces the number of advanced aberrant crypt foci and attenuates the expression of colonic transforming growth factor beta and cyclooxygenase isoforms in Zucker obese (fa/fa) rats. Cancer Res 63:6595-01.
123. Rappaport SM. 2012. Biomarkers intersect with the exposome. Biomarkers 17:483-9.
124. Rein MJ, Renouf M, Cruz-Hernandez C, Actis-Goretta L, Thakkar SK, da Silva Pinto M. 2013. Bioavailability of bioactive food compounds: a challenging journey to bioefficacy. Br J Clin Pharmacol 75:588-602.
125. Reis JM, Sinko B, Serra CH. 2010. Parallel artificial membrane permeability assay (PAMPA) - is it better than Caco-2 for human passive permeability prediction? Mini Rev Med Chem 10:1071-6.
126. Rickman C, Medine CN, Bergmann A, Duncan RR. 2007. Functionally and spatially distinct modes of munc18-syntaxin 1 interaction. J Biol Chem 282:12097-103.
127. Roblegg E, Frohlich E, Meindl C, Teubl B, Zaversky M, Zimmer A. 2012. Evaluation of a physiological in vitro system to study the transport of nanoparticles through the buccal mucosa. Nanotoxicology 6:399-413.
128. Rogers KR, Bradham K, Tolaymat T, Thomas DJ, Hartmann T, Ma L, Williams A. 2012. Alterations in physical state of silver nanoparticles exposed to synthetic human stomach fluid. Sci Total Environ 420: 334-9.
129. Rouleau L, Berti R, Ng VW, Matteau-Pelletier C, Lam T, Saboural P, et al. 2013. VCAM-1-targeting gold nanoshell probe for photoacoustic imaging of atherosclerotic plaque in mice. Contrast Media Mol Imaging 8:27-39.
130. Rozehnal V, Nakai D, Hoepner U, Fischer T, Kamiyama E, Takahashi M, et al. 2012. Human small intestinal and colonic tissue mounted in the ussing chamber as a tool for characterizing the intestinal absorption of drugs. Eur J Pharm Sci 46:367-73.
131. Rubas W, Cromwell ME, Shahrokh Z, Villagran J, Nguyen TN, Wellton M, et al. 1996. Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J Pharm Sci 85: 165-9.
132. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. 2004. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026-46.
133. Russell TL, Berardi RR, Barnett JL, Dermentzoglou LC, Jarvenpaa KM, Schmaltz SP, Dressman JB. 1993. Upper gastrointestinal ph in seventynine healthy, elderly, north american men and women. Pharm Res 10: 187-96.
134. Salles C, Tarrega A, Mielle P, Maratray J, Gorria P, Liaboeuf J, Liodenot JJ. 2007. Development of a chewing simulator for food breakdown and the analysis of in vitro flavor compound release in a mouth environment. J Food Eng 82:189-98.
135. Salman HH, Gamazo C, Agueros M, Irache JM. 2007. Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles. Vaccine 25:8123-32.
136. Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A, Zucco F. 2005. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol 21:1-26.
137. Sandri G, Bonferoni MC, Rossi S, Ferrari F, Gibin S, Zambito Y, et al. 2007. Nanoparticles based on n-trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. Eur J Pharm Biopharm 65:68-77.
138. Schmidt C, Lautenschlaeger C, Collnot EM, Schumann M, Bojarski C, Schulzke JD, et al. 2013. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients. J Control Release 165:139-45.
139. Shahbazi MA, Santos HA. 2013. Improving oral absorption via drugloaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication. Curr Drug Metab 14:28-56.
140. Singh G, Stephan C, Westerhoff P, Carlander D, Duncan TV. 2014. Measurement methods to detect, characterize, and quantify engineered nanomaterials in foods. Compr Rev Food Sci Food Saf 13:693-704.
141. Sinha VK, Snoeys J, Osselaer NV, Peer AV, Mackie C, Heald D. 2012. From preclinical to human - prediction of oral absorption and drugdrug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example. Biopharm Drug Dispos 33:111-21.
142. Sonaje K, Chuang EY, Lin KJ, Yen TC, Su FY, Tseng MT, Sung HW. 2012. Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. Mol Pharm 9:1271-9.
143. Souliman S, Beyssac E, Cardot JM, Denis S, Alric M. 2007. Investigation of the biopharmaceutical behavior of theophylline hydrophilic matrix tablets using USP methods and an artificial digestive system. Drug Dev Ind Pharm 33:475-83.
144. Souliman S, Blanquet S, Beyssac E, Cardot JM. 2006. A level a in vitro/in vivo correlation in fasted and fed states using different methods: applied to solid immediate release oral dosage form. Eur J Pharm Sci 27:72-9.
145. Sozer N, Kokini JL. 2009. Nanotechnology and its applications in the food sector. Trends Biotechnol 27:82-9.
146. Stone V, Pozzi-Mucelli S, Tran L, Aschberger K, Sabella S, Vogel U, et al. 2014. ITS-NANO - prioritising nanosafety research to develop a stakeholder driven intelligent testing strategy. Part Fibre Toxicol 11:9. doi:10.1186/1743-8977-11-9.
147. Suenderhauf C, Hammann F, Maunz A, Helma C, Huwyler J. 2011. Combinatorial QSAR modeling of human intestinal absorption. Mol Pharm 8:213-24.
148. Sugano K. 2009. Introduction to computational oral absorption simulation. Exp Opin Drug Metab Toxicol 5:259-93.
149. Szakal C, Roberts SM, Westerhoff P, Bartholomaeus A, Buck N, Illuminato I, et al. (2014a). Measurement of nanomaterials in foods: integrative consideration of challenges and future prospects. ACS Nano 8:3128-35.
150. Szakal C, Tsytsikova L, Carlander D, Duncan TV. (2014b). Measurement methods for the oral uptake of engineered nanomaterials from human dietary sources: summary and outlook. Compr Rev Food Sci Food Saf 13:669-78.
151. Tanaka T. 2012. Animal models of carcinogenesis in inflamed colorectum: potential use in chemoprevention study. Curr Drug Targets 13:1689-97.
152. Tavelin S, Taipalensuu J, Soderberg L, Morrison R, Chong S, Artursson P. 2003. Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/a1 cell monolayers. Pharm Res 20: 397-405.
153. Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG. 2007. Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol Sci 95:300-12.
154. Teubl BJ, Absenger M, Frohlich E, Leitinger G, Zimmer A, Roblegg E. 2013. The oral cavity as a biological barrier system: design of an advanced buccal in vitro permeability model. Eur J Pharm Biopharm 84:386-93.
155. Thomas C, Oates PS. 2002. IEC-6 cells are an appropriate model of intestinal iron absorption in rats. J Nutr 132:680-7.
156. Thomas K, Aalbers M, Bannon GA, Bartels M, Dearman RJ, Esdaile DJ, et al. 2004. A multi-laboratory evaluation of a common in vitro pepsin digestion assay protocol used in assessing the safety of novel proteins. Regul Toxicol Pharmacol 39:87-98.
157. Tryndyak V, de Conti A, Kobets T, Kutanzi K, Koturbash I, Han T, et al. 2012. Interstrain differences in the severity of liver injury induced by a choline- and folate-deficient diet in mice are associated with dysregulation of genes involved in lipid metabolism. FASEB J 26: 4592-602.
158. Tyrer P, Ruth Foxwell A, Kyd J, Harvey M, Sizer P, Cripps A. 2002. Validation and quantitation of an in vitro M-cell model. Biochem Biophys Res Commun 299:377-83.
159. Valerio Jr LG, Balakrishnan S, Fiszman ML, Kozeli D, Li M, Moghaddam S, Sadrieh N. 2013. Development of cardiac safety translational tools for QT prolongation and torsade de pointes. Exp Opin Drug Metab Toxicol 9:801-15.
160. Van de Wiele TR, Oomen AG, Wragg J, Cave M, Minekus M, Hack A, et al. 2007. Comparison of five in vitro digestion models to in vivo experimental results: lead bioaccessibility in the human gastrointestinal tract. J Environ Sci Health A Tox Hazard Subst Environ Eng 42: 1203-11.
161. van der Zande M, Vandebriel RJ, Van Doren E, Kramer E, Herrera Rivera Z, Serrano-Rojero CS, et al. 2012. Distribution, elimination, and toxicity of silver nanoparticles and silver ions in rats after 28-day oral exposure. ACS Nano 6:7427-42.
162. Vergeres G, Bogicevic B, Buri C, Carrara S, Chollet M, Corbino- Giunta L, et al. 2012. The nutrichip project-translating technology into nutritional knowledge. Br J Nutr 108:762-8.
163. Versantvoort CH, Ondrewater RC, Duizer E, Van de Sandt JJ, Gilde AJ, Groten JP. 2002. Monolayers of IEC-18 cells as an in vitro model for screening the passive transcellular and paracellular transport across the intestinal barrier: comparison of active and passive transport with the human colon carcinoma Caco-2 cell line. Environ Toxicol Pharmacol 11:335-44.
164. Versantvoort CH, Oomen AG, Van de Kamp E, Rompelberg CJ, Sips AJ. 2005. Applicability of an in vitro digestion model in assessing the bioaccessibility of mycotoxins from food. Food Chem Toxicol 43: 31-40.
165. Volpe DA. 2010. Application of method suitability for drug permeability classification. AAPS J 12:670-8.
166. Walczak AP, Fokkink R, Peters R, Tromp P, Herrera Rivera ZE, Rietjens IM, et al. 2013. Behaviour of silver nanoparticles and silver ions in an in vitro human gastrointestinal digestion model. Nanotoxicology 7: 1198-210.
167. Walter E, Janich S, Roessler BJ, Hilfinger JM, Amidon GL. 1996. HT29- MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci 85:1070-6.
168. Wang C, Qiao L, Zhang Q, Yan H, Liu K. 2012. Enhanced cell uptake of superparamagnetic iron oxide nanoparticles through direct chemisorption of FITC-TaT-PEG600-b-poly(glycerol monoacrylate). Int J Pharm 430:372-80.
169. Watson C, Ge J, Cohen J, Pyrgiotakis G, Engelward BP, Demokritou P. 2014. High-throughput screening platform for engineered nanoparticle- mediated genotoxicity using comet chip technology. ACS Nano 8: 2118-33.
170. Wickham M, Faulks R, Mills C. 2009. In vitro digestion methods for assessing the effect of food structure on allergen breakdown. Mol Nutr Food Res 53:952-8.
171. Will OC, Man RF, Phillips RK, Tomlinson IP, Clark SK. 2008. Familial adenomatous polyposis and the small bowel: a loco-regional review and current management strategies. Pathol Res Pract 204: 449-58.
172. Winkler DA, Mombelli E, Pietroiusti A, Tran L, Worth A, Fadeel B, McCall MJ. 2012. Applying quantitative structure-Activity relationship approaches to nanotoxicology: current status and future potential. Toxicology 313:15-23.
173. Yada R, Buck N, Canady C, DeMerlis C, Duncan T, Janer G, et al. 2014. Engineered nanoscale food ingredients: evaluation of current knowledge on material characteristics relevant to uptake from the gastrointestinal tract. Compr Rev Food Sci Food Saf 13:730-44.
174. Yadev NP, Murdoch C, Saville SP, Thornhill MH. 2011. Evaluation of tissue engineered models of the oral mucosa to investigate oral candidiasis. Microb Pathog 50:278-85.
175. Yan YD, Woo JS, Kang JH, Yong CS, Choi HG. 2010. Preparation and evaluation of taste-masked donepezil hydrochloride orally disintegrating tablets. Biol Pharm Bull 33:1364-70.
176. Youdim KA, Avdeef A, Abbott NJ. 2003. In vitro trans-monolayer permeability calculations: often forgotten assumptions. Drug Discov Today 8:997-1003.
177. Yu J, Peng S, Luo D, March JC. 2012. In vitro 3D human small intestinal villous model for drug permeability determination. Biotechnol Bioeng 109:2173-8.
178. Yu LX, Amidon GL. 1999. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 186: 119-25.
179. Yuan H, Chen CY, Chai GH, Du YZ, Hu FQ. 2013. Improved transport and absorption through gastrointestinal tract by pegylated solid lipid nanoparticles. Mol Pharm 10:1865-73.
180. Yuan H, Chen J, Du YZ, Hu FQ, Zeng S, Zhao HL. 2007. Studies on oral absorption of stearic acid SLN by a novel fluorometric method. Colloids Surf B Biointerfaces 58:157-64.
181. Zariwala MG, Elsaid N, Jackson TL, Corral Lopez F, Farnaud S, Somavarapu S, Renshaw D. 2013. A novel approach to oral iron delivery using ferrous sulphate loaded solid lipid nanoparticles. Int J Pharm 456:400-7.
182. Zeineldin M, Neufeld KL. 2013. More than two decades of Apc modeling in rodents. Biochim Biophys Acta 1836:80-9.
183. Zhang S, Moss SF. 2012. Rodent models of helicobacter infection, inflammation, and disease. Methods Mol Biol 921: 89-98.
184. Zolotarevsky Y, Hecht G, Koutsouris A, Gonzalez DE, Quan C, Tom J, et al. 2002. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 123:163-72.